Marktanalyse - Autism - Pipeline Review, H1 2017

Global Markets Direct
02.2017
125 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Autism - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism — Pipeline Review, H1 2017, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 1, 15, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Autism - Overview

Autism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Autism - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

AgeneBio Inc

Anima Biotech Ltd

APeT Holding BV

Avanir Pharmaceuticals Inc

BioCrea GmbH

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Confluence Pharmaceuticals LLC

Coronis NeuroSciences Ltd

Curemark LLC

DRI Biosciences Corp

F. Hoffmann-La Roche Ltd

GW Pharmaceuticals Plc

Heptares Therapeutics Ltd

Immuron Ltd

Intra-Cellular Therapies Inc

Leading BioSciences Inc

MedDay SA

Omeros Corp

OptiNose US Inc

Sumitomo Chemical Co Ltd

Autism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Autism - Drug Profiles

(dextromethorphan + quinidine sulfate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acamprosate calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-88178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aripiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-0306 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-AT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GWP-42006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

histamine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-14242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumateperone tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niacinamide CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NurOwn - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Insulin Like Growth Factor 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-999 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Chloride Channels for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR63 for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Autism - Dormant Projects

Autism - Discontinued Products

Autism - Product Development Milestones

Featured News & Press Releases

Sep 22, 2016: Blum Study - A Phase 3 Clinical Trial for Children with Autism

Jul 20, 2016: Immuron to Cooperate with Leading Australian Universities on Autism Research

Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch

Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole

May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism

Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment

Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt

Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis

Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz

Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism

Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors

Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism

May 31, 2012: Study Reports New Treatment For Irritability In Autism

Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism

Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Autism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Autism - Pipeline by Addex Therapeutics Ltd, H1 2017

Autism - Pipeline by Aequus Pharmaceuticals Inc, H1 2017

Autism - Pipeline by AgeneBio Inc, H1 2017

Autism - Pipeline by Anima Biotech Ltd, H1 2017

Autism - Pipeline by APeT Holding BV, H1 2017

Autism - Pipeline by Avanir Pharmaceuticals Inc, H1 2017

Autism - Pipeline by BioCrea GmbH, H1 2017

Autism - Pipeline by BioHealthonomics Inc, H1 2017

Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017

Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2017

Autism - Pipeline by Coronis NeuroSciences Ltd, H1 2017

Autism - Pipeline by Curemark LLC, H1 2017

Autism - Pipeline by DRI Biosciences Corp, H1 2017

Autism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Autism - Pipeline by GW Pharmaceuticals Plc, H1 2017

Autism - Pipeline by Heptares Therapeutics Ltd, H1 2017

Autism - Pipeline by Immuron Ltd, H1 2017

Autism - Pipeline by Intra-Cellular Therapies Inc, H1 2017

Autism - Pipeline by Leading BioSciences Inc, H1 2017

Autism - Pipeline by MedDay SA, H1 2017

Autism - Pipeline by Omeros Corp, H1 2017

Autism - Pipeline by OptiNose US Inc, H1 2017

Autism - Pipeline by Sumitomo Chemical Co Ltd, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Autism - Dormant Projects, H1 2017

Autism - Dormant Projects, H1 2017 (Contd..1), H1 2017

Autism - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Autism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus